Article Text

Download PDFPDF
21 GROWTH, MOTOR, AND SOCIAL DEVELOPMENT IN BREAST- AND FORMULA-FED INFANTS OF METFORMIN-TREATED WOMEN WITH POLYCYSTIC OVARY SYNDROME.
  1. C. J. Glueck,
  2. M. Salehi,
  3. L. Sieve,
  4. P. Wang
  1. Cholesterol Center, Jewish Hospital, Cincinnati, OH

Abstract

Objectives In a prospective, 6-month study of 61 breast- and 50 formula-fed infants born to 92 PCOS mothers, all of whom took metformin throughout pregnancy, our hypothesis was that metformin during lactation vs formula would have no adverse effects on infants' growth, motor-social development, and intercurrent illness.

Study Design Growth, motor-social development, and illness requiring a pediatrician visit were prospectively assessed in 61 nursing infants (21 male, 40 female) and 50 formula-fed infants (19 male, 31 female) born to 92 PCOS mothers taking a median of 2.55 g metformin/day throughout pregnancy and lactation.

Results Within gender, at 3 and 6 months of age, weight, height, and motor-social development did not differ (p $ .06) between breast- and formula-fed infants. No infants had retardation of growth, motor, or social development. Intercurrent illnesses did not differ in 30% of breast- and 22% of formula-fed infants by 3 months (p = .4) and in 46% and 34% by 6 months (p = .2).

Conclusions Growth, motor-social development, and intercurrent illnesses in breast- and formula-fed infants from metformin-treated PCOS mothers did not differ; metformin during lactation appears to be safe and effective in the first 6 months of infancy.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.